Current Edition

FDA focuses on innovative trial designs
Volume 10 Issue 3

FDA Focuses On Innovative Trial Designs

The US Food and Drug Administration (FDA) is seeking stakeholder input on the use of complex innovative designs (CIDs) in drug development and regulatory decision-making. …

Continue Reading →
How far can AI go in life sciences
Volume 10 Issue 3

How Far Can AI Go in Life Sciences?

Artificial intelligence (AI) and machine learning are everywhere; intelligent internet and content searches that adapt to user preferences, automated personal assistants like Alexa and Siri, …

Continue Reading →
Respiratory network for early phase
Volume 10 Issue 3

Respiratory Network for Early-phase Clinical Trials

The biopharmaceutical industry has a growing need for early-phase clinical studies in respiratory patients to support more advanced and informed “go/no-go” decisions in drug development, …

Continue Reading →
Stay with us achieving retention during
Volume 10 Issue 3

Stay with Us: Achieving Retention During Long-term Follow-up in Gene Therapy Clinical Trials

Gene therapy clinical trials differ in notable ways from other kinds of clinical trials. For one thing, patients in a typical Phase III clinical trial …

Continue Reading →
Implementation of ICH E6 R2
Volume 10 Issue 3

Implementation of ICH E6 R2 – An Overview of Key Changes

After release of the final draft of ICH E6 R2 in November 2016, the regulatory bodies started announcing the implementation of E6 R2 one after …

Continue Reading →
FDAs roadmap to combat the gender gap
Volume 10 Issue 3

FDA’s Roadmap to Combat the Gender Gap in Clinical Research

Amidst growing concern that the needs of women are being overlooked by academics and pharmaceutical companies, the FDA’s Office of Women’s Health (OWH) has released …

Continue Reading →
Central haemodynamic assessments mitigate
Volume 10 Issue 3

Central Haemodynamic Assessments Mitigate Risks in Drug Development

Given high costs and low success rates, risk mitigation strategies are critical in drug development. Pharmaceutical companies and investors are continually looking for ways to …

Continue Reading →
How to prevent poor patient enrolment
Volume 10 Issue 3

How to Prevent Poor Patient Enrolment from Derailing a Clinical Trial

A recent study by researchers at McGill University’s Biomedical Ethics Unit found that one in five clinical trials is terminated for failing to recruit enough …

Continue Reading →
Staff turnover is lower healthier
Volume 10 Issue 3

Staff Turnover: Is Lower Healthier?

Evgeny Poltanov at Synergy discusses the CRO’s staff turnover and how anyone can guarantee a completely stable team when it comes to longer-term trials. He …

Continue Reading →
Patient centricity a winning formula
Volume 10 Issue 3

Patient-centricity – A Winning Formula

There has been considerable discussion about the concept of patientcentricity in the pharmaceutical community. The industry has taken a collective pause in an effort to …

Continue Reading →